11 results about "Rituximab" patented technology

The invention discloses an antigen expression vector, a combination of the antigen expression vector and an antibody and application of the combination in cancer treatment. The antigen expression vector comprises one or more DMP-antigen coding gene units; the DMP-antigen coding gene is composed of two functional elements DMP and an antigen coding gene, the DMP is an NF-kappa B specific promoter, and the antigen coding gene is an antigen molecule coding sequence. The antigen expression vector prepared by the invention can selectively express antigen molecules in cancer cells, an in-vivo delivery vector taking adeno-associated virus as the antigen expression vector, and a combination of an antigen CD20 expressed by the antigen expression vector and an anti-CD20 antibody rituximab. The compound has a good treatment effect on mouse colon cancer on mice and human colon cancer on humanized mice, and has good tumor targeting property and safety in the treatment of the cancer mice. The invention is expected to provide a new technology and a new reagent for the treatment of various cancer diseases.

This disclosure includes methods for treating cancer in a subject, the method comprising administering an anti-CD20 antibody and an immune cell expressing a therapeutic polypeptide (e.g., a TEAM) to the subject.

The invention provides targeted precise immunotherapy by applying a biological protein nano-robot to carry a biological agent and a preparation method of the biological protein nano-robot, and relates to the field of immunotherapy, the preparation method comprises the following steps: S100, preparing a serum albumin aqueous solution with the serum albumin concentration of 5-10% w / v, and a phosphate buffer solution with the pH value of 7.4 as a solvent; and S200, preparing an organic solution of a hydrophobic anti-rheumatism drug, wherein the drug is one or more of adalimumab, jucuiliumab, ezetizumab, tetronigerb, tolzumab and rituximab. When the albumin nano-robot targeting drug is used for treating rheumatism, effective targeting can be realized by utilizing the chemotactic effect of the albumin nano-robot targeting drug for immunotherapy on high-expression iNOS and ROS in an immune microenvironment, and the released anti-rheumatism drug and nitric oxide play a synergistic effect for combined treatment; wherein the anti-rheumatism medicine and nitric oxide (NO) generated in the targeting process of the nano-robot can jointly start immune circulation in vivo, and the anti-rheumatism medicine and the nitric oxide (NO) cooperate with the chemotherapy medicine to achieve the killing effect, so that the combined treatment effect is achieved.

Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

This document relates to methods and materials involved in identifying and / or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a Semaphorin 3B polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more immunosuppressive agents (e.g., corticosteroids, cyclosporine, or a B-cell reduction or depletion agent such as Rituximab) to treat a mammal (e.g., a human) having membranous nephropathy are provided.

This invention relates to a preparation process of litexitinib tosylate. In the preparation process described in this invention, the raw material undergoes an amidation reaction of a carbonyl group and an amino group. After the amide is reduced, it is resolved by L-DBTA to obtain the desired chiral compound, and finally, it is salted with p-methanesulfonic acid to yield the target compound. The preparation process of this invention uses a readily available chiral isomer as the raw material, avoiding the two chiral column separations required in existing methods, thus offering better economic efficiency. Furthermore, the resolving agent L-DBTA is inexpensive and readily available, avoiding expensive reagents; the reaction is mild, the operation is safe, and the separation is highly secure; column chromatography purification is avoided, facilitating industrial production.

Provided is use of NK cells in treating vitiligo and psoriasis. Specifically, provided are use of NK cells and a cancer-targeted drug in the preparation of a drug for treating patients with primary liver cancer or hepatocellular carcinoma accompanied by psoriasis, and use of NK cells and rituximab in the preparation of a drug for treating patients with hepatic cyst accompanied by psoriasis.

The invention discloses a culture method of umbilical cord mesenchymal stem cells for treating cognitive impairment, and belongs to the technical field of cell culture. The culture method specifically comprises the following steps: (1) preparing a special culture medium; (2) umbilical cord pretreatment; and (3) cell culture. The traditional Chinese medicine extract (astragaloside), the B cell depleting agent (rituximab and ibrutinib) and the metabolism regulator (eicosapentaenoic acid) are jointly applied to the UC-MSCs in-vitro culture process, the multiplication capacity, the anti-inflammatory characteristic and the neural restoration function of the UC-MSCs can be synergistically enhanced, and therefore the cognitive disorder treatment efficiency of the UC-MSCs is remarkably improved.

The invention discloses a targeted immunomodulatory fusion protein for treating systemic lupus erythematosus, an engineered stem cell preparation for expressing the fusion protein as well as a preparation method and application of the engineered stem cell preparation. The fusion protein is composed of an anti-human CD20 single-chain antibody, an enhanced human IL-10 variant and a flexible connecting peptide, the complete amino acid sequence is SEQ ID NO5, the affinity to CD20 is basically equivalent to or better than that of rituximab, and the IL-10 activity is 1.8 times that of a wild type. The engineered stem cell preparation is obtained by transfecting human umbilical cord mesenchymal stem cells through lentivirus and screening puromycin, and the preparation can stably secrete fusion protein and is specifically combined with CD20 positive B cells. In-vitro experiments prove that B cell proliferation and IgG secretion can be remarkably inhibited, the urine protein positive rate and the dsDNA IgG level can be reduced in an in-vivo MRL / lpr mouse model, kidney pathological injuries are relieved, and the survival rate is increased. Precise treatment is achieved through a synergistic mechanism of targeted enrichment and local high-activity IL-10 delivery, the side effect of systemic immunosuppression is avoided, and the clinical transformation value is high.

Provided are methods for inducing apoptosis of cells. The cells may be cancer cells (e.g., lymphoma cells). The cancer cells may be resistant to other known therapies, such as, for example, therapy with rituximab, a chimeric anti-CD20 monoclonal antibody. A method can include contacting the cells with a compound having the following structure: (MMRi36).